Temperature-controlled supply chain solutions firm Cryoport has announced the opening of a new 13,400 sq ft IntegriCell™ facility in Villers-le-Bouillet, Liege, Belgium.
Already operational, the site will develop, optimise, and validate cryogenic preservation methods for leukapheresis materials used in cell-based therapies.
The facility has the capacity to cryopreserve over 1,100 leukapheresis products annually.
News of the new facility comes just over a month after the company announced a similar site in Houston in support of its InteriCell bioprocessing, cryopreservation, and distribution solution for the cell therapy market.
Read more: Cryoport opens Houston site for IntegriCell cryopreservation
Jerrell Shelton, CEO of Cryoport, said that the Belgium site, paired with the Houston location, will provide the industry with a critical resource to standardise and improve how we preserve cellular starting materials.
“With room for future expansion, this facility is designed to adapt and expand with our clients’ and the market’s evolving needs,” he added.
Cryoport’s IntegriCell Belgium site will transfer its developed optimised cryopreservation processes to other Cryoport facilities. Cryoport now has 13 facilities, including cryopreservation centres, bioservices centres, logistics centres, supply chain centres, and officers.
The life sciences industry requires a robust shipping system at cryogenic temperatures that can handle the risks associated with transporting high-value commodities such as advanced therapies. Slight temperature deviations can render the commodity ineffective, and minor physical damage can also damage its usability.
With so much at stake, advanced therapy developers and manufacturers need an advanced packaging system that can maintain consistent temperatures to deliver raw materials, viral vectors, and gene therapies in perfect condition.
According to Nova One Advisor, the global cell and gene therapy market size was valued at $18.13bn in 2023 but is expected to reach around $97.33bn in 2033, growing at a CAGR of 18.3% from 2024 to 2033.
European CO2 Summit 2025: Rotterdam
The conversation around carbon dioxide (CO2) is changing, with a focus on its value as part of a circular economy. Join The European CO2 Summit in Rotterdam this March to explore the future of the CO2 business in Europe and its alignment with decarbonisation efforts. Expect market insights, emerging technologies, panel discussions, and networking opportunities.
Learn more: https://bit.ly/Europeanco2summit2025-F
